Gilles Fenelon

Summary

Country: France

Publications

  1. ncbi [Psychotic symptoms in Parkinson's disease]
    Gilles Fenelon
    Service de Neurologie, Hopital Henri Mondor, Creteil
    Psychol Neuropsychiatr Vieil 4:S17-24. 2006
  2. pmc Feeling of presence in Parkinson's disease
    Gilles Fenelon
    1AP HP, Groupe HospitalierHenri Mondor, Service deneurologie, Cre teil, France
    J Neurol Neurosurg Psychiatry 82:1219-24. 2011
  3. pmc The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria
    Gilles Fenelon
    AP HP, Department of Neurology, CHU Henri Mondor, Creteil, France
    Mov Disord 25:763-6. 2010
  4. ncbi Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms
    Gilles Fenelon
    Department of Neurology, Henri Mondor Hospital, Creteil, France
    CNS Spectr 13:18-25. 2008
  5. ncbi [Psychological and behavioural disorders in Parkinson's disease]
    Gilles Fenelon
    Neurologie, APHP, Groupe Hospitalier Henri Mondor 94000 Créteil, INSERM U955, Equipe 1, Institut Mondor pour la Recherche Biomédicale, 94000 Creteil
    Bull Acad Natl Med 194:1305-18; discussion 1318-9. 2010
  6. ncbi Hallucinations in Parkinson disease in the prelevodopa era
    Gilles Fenelon
    Department of Neurology, Hopital Henri Mondor, AP HP, Creteil, France
    Neurology 66:93-8. 2006
  7. ncbi [Parkinson's disease: dealing with all dimensions of the disease]
    Gilles Fenelon
    Service de neurologie et équipe A venir Inserm U421, Hopital Henri Mondor, 94010 Creteil Cedex
    Rev Prat 55:714-6. 2005
  8. ncbi [Management of psychiatric complications of Parkinson's disease]
    Gilles Fenelon
    Service de neurologie et Inserm U421, Equipe Avenir, CHU Henri Mondor, 94010 Creteil Cedex
    Rev Prat 55:733-9. 2005
  9. doi Epidemiology of psychosis in Parkinson's disease
    Gilles Fenelon
    AP HP, CHU Henri Mondor, Creteil, France
    J Neurol Sci 289:12-7. 2010
  10. doi Depression and coping as predictors of change after deep brain stimulation in Parkinson's disease
    Thierry Soulas
    Institut de Psychologie, Universite Paris Descartes, Paris, France
    World Neurosurg 75:525-32. 2011

Detail Information

Publications19

  1. ncbi [Psychotic symptoms in Parkinson's disease]
    Gilles Fenelon
    Service de Neurologie, Hopital Henri Mondor, Creteil
    Psychol Neuropsychiatr Vieil 4:S17-24. 2006
    ..Cholinesterase inhibitors, when prescribed for associated cognitive impairment, may be beneficial on hallucinations. In the more severe forms, clozapine has been proved to be safe and effective...
  2. pmc Feeling of presence in Parkinson's disease
    Gilles Fenelon
    1AP HP, Groupe HospitalierHenri Mondor, Service deneurologie, Cre teil, France
    J Neurol Neurosurg Psychiatry 82:1219-24. 2011
    ..The objective of this study was to provide a detailed description of FP in PD and to discuss its possible mechanisms...
  3. pmc The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria
    Gilles Fenelon
    AP HP, Department of Neurology, CHU Henri Mondor, Creteil, France
    Mov Disord 25:763-6. 2010
    ..Minor symptoms and nonvisual hallucinations are an important part of the PDAP spectrum, which has commonly been restricted to visual hallucinations and delusions...
  4. ncbi Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms
    Gilles Fenelon
    Department of Neurology, Henri Mondor Hospital, Creteil, France
    CNS Spectr 13:18-25. 2008
    ..Pathogenesis involves complex and probably multifactorial mechanisms, including pharmacologic (dopaminergic treatment and others) and disease-related factors...
  5. ncbi [Psychological and behavioural disorders in Parkinson's disease]
    Gilles Fenelon
    Neurologie, APHP, Groupe Hospitalier Henri Mondor 94000 Créteil, INSERM U955, Equipe 1, Institut Mondor pour la Recherche Biomédicale, 94000 Creteil
    Bull Acad Natl Med 194:1305-18; discussion 1318-9. 2010
    ..These disorders are often difficult to manage, and there is an unmet need for controlled trials in this field...
  6. ncbi Hallucinations in Parkinson disease in the prelevodopa era
    Gilles Fenelon
    Department of Neurology, Hopital Henri Mondor, AP HP, Creteil, France
    Neurology 66:93-8. 2006
    ..Even with these limitations, historical descriptions of PD from the prelevodopa era suggest that hallucinations may be part of PD itself, especially in the context of late dementia, depression, or nonspecific encephalopathy...
  7. ncbi [Parkinson's disease: dealing with all dimensions of the disease]
    Gilles Fenelon
    Service de neurologie et équipe A venir Inserm U421, Hopital Henri Mondor, 94010 Creteil Cedex
    Rev Prat 55:714-6. 2005
  8. ncbi [Management of psychiatric complications of Parkinson's disease]
    Gilles Fenelon
    Service de neurologie et Inserm U421, Equipe Avenir, CHU Henri Mondor, 94010 Creteil Cedex
    Rev Prat 55:733-9. 2005
    ..Depression, anxiety and hallucinations are common but may be underestimated. During recent years, new psychiatric aspects have been described such as apathy and the so-called syndrome of dopamine dysregulation...
  9. doi Epidemiology of psychosis in Parkinson's disease
    Gilles Fenelon
    AP HP, CHU Henri Mondor, Creteil, France
    J Neurol Sci 289:12-7. 2010
    ..PDP reduces quality of life in patients and increases caregiver distress, and is an independent risk factor for nursing home placement and development of dementia...
  10. doi Depression and coping as predictors of change after deep brain stimulation in Parkinson's disease
    Thierry Soulas
    Institut de Psychologie, Universite Paris Descartes, Paris, France
    World Neurosurg 75:525-32. 2011
    ..This study examined changes in motor function and quality of life (QoL) after subthalamic nuclei deep brain stimulation (STN-DBS) in patients with Parkinson disease (PD) and the role of psychosocial predictors on individual changes...
  11. ncbi Hallucinations in Parkinson's disease: a follow-up study
    Anne Doe de Maindreville
    Service de Neurologie, Hopital Maison Blanche, Reims, France
    Mov Disord 20:212-7. 2005
    ..2-27.4). Hallucinations have a chronic course in most parkinsonian patients. Factors predicting the onset of hallucinations point to a role of extranigral brainstem involvement and a nonspecific, facilitating role of ocular disorders...
  12. doi Can nicotine be used medicinally in Parkinson's disease?
    Claire Thiriez
    Department of Neurology, University Hospital Henri Mondor and Paris 12 University UPEC, Creteil, France
    Expert Rev Clin Pharmacol 4:429-36. 2011
    ..Together, these data suggest that nicotine or nicotinic receptor drugs have therapeutic potential for Parkinson's disease, although the specific treatment regimens remain to be determined...
  13. ncbi Vascular parkinsonism
    Igor Sibon
    Service de Neurologie, Hopital Haut Lévèque Groupe Hospitalier Sud, CHU de Bordeaux, Av de Magellan, 33600, Pessac, France
    J Neurol 251:513-24. 2004
    ..The pathophysiology of VP is poorly understood. Why some patients develop parkinsonism and others do not, despite the same apparent lesion load, remains a mystery...
  14. ncbi [Visual hallucinations: the Charles Bonnet syndrome]
    Gilles Fenelon
    Service de Neurologie, Hopital Henri Mondor, Creteil
    Psychol Neuropsychiatr Vieil 1:121-7. 2003
    ..Finally, visual impairment appear as a non specific risk factor for VH in some conditions such as late paraphrenia and some neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease...
  15. pmc Awareness of memory deficits in early stage Huntington's disease
    Laurent Cleret de Langavant
    Inserm U955 E01, Neuropsychologie Interventionnelle, Creteil, France
    PLoS ONE 8:e61676. 2013
    ..Loss of awareness of memory deficits in HD is associated with the severity of the disease in terms of CAG repeats, functional decline, motor dysfunction and cognitive impairment, including memory deficits and executive dysfunction...
  16. doi A reappraisal of long-latency abdominal muscle reflexes in patients with propriospinal myoclonus
    Samar S Ayache
    Service de Physiologie Explorations Fonctionnelles, Hopital Henri Mondor, APHP, EA 4391, Faculté de Médecine de Créteil, Université Paris Est Créteil, Creteil, France
    Mov Disord 26:1759-63. 2011
    ..We report 3 patients with typical clinical and electrophysiological characteristics of propriospinal myoclonus propagating from a thoracic spine generator...
  17. doi Outcome of bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease: correlation with intra-operative multi-unit recordings but not with the type of anaesthesia
    Jean Pascal Lefaucheur
    Services de Physiologie, Explorations Fonctionnelles, Hopital Henri Mondor, Assistance Publique, Hopitaux de Paris, Creteil, France
    Eur Neurol 60:186-99. 2008
    ..Deep brain stimulation (DBS) of the subthalamic nucleus (STN) gained general acceptance in the treatment of Parkinson's disease (PD)...
  18. ncbi Head tremor in Parkinson's disease
    Emmanuel Roze
    Department of Neurology, Saint Antoine Hospital, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Mov Disord 21:1245-8. 2006
    ..We describe five patients with Parkinson's disease and head tremor in whom clinical and neurophysiological findings suggested that head tremor was a manifestation of Parkinson's disease...
  19. ncbi Tactile hallucinations in Parkinson's disease
    Gilles Fenelon
    Service de Neurologie, Hopital Henri Mondor, 94010 Creteil Cedex, France
    J Neurol 249:1699-703. 2002
    ..Pharmacological and disease-related factors, including a disorder in rapid-eye-movement sleep mechanisms, could play a part in the pathophysiology of these hallucinations...